Related Experiment Videos
New aspects of injectable contraception.
1Department of Obstetrics and Gynecology, University of Tennessee, Memphis 38103, USA.
International Journal of Fertility and Women'S Medicine
|April 11, 2001
Summary
New monthly injectable contraceptives offer improved menstrual regulation and faster fertility return compared to older three-month injections. However, estrogen-containing options are unsuitable for some women.
Area of Science:
- Reproductive Health
- Endocrinology
- Contraception
Background:
- Despite numerous contraceptive options, unmet needs persist.
- Injectable contraceptives offer convenience and improve compliance.
- Existing long-acting injectables like depot medroxyprogesterone acetate (DMPA) have drawbacks such as irregular bleeding and delayed fertility return.
Purpose of the Study:
- To introduce and evaluate a new monthly injectable contraceptive, medroxyprogesterone acetate/estradiol cypionate suspension (Lunelle).
- To highlight the benefits of Lunelle, including menstrual regulation and rapid return to fertility.
- To identify contraindications for Lunelle use, specifically those related to estrogen.
Main Methods:
- Comparison of Lunelle (medroxyprogesterone acetate/estradiol cypionate suspension) with existing injectable contraceptives.
- Evaluation of Lunelle's efficacy, side effect profile, and impact on menstrual regularity.
- Assessment of the return to fertility timeline post-discontinuation of Lunelle.
Main Results:
- Lunelle provides monthly withdrawal bleeds due to its estrogen component.
- It offers a more predictable bleeding pattern compared to DMPA.
- Lunelle facilitates a quicker return to fertility after cessation of use.
Conclusions:
- Lunelle presents a viable alternative for women seeking monthly injectable contraception.
- Menstrual regulation and rapid fertility return are key advantages.
- Women with contraindications to estrogen-containing contraceptives cannot use Lunelle.